Compare CANbridge Pharmaceuticals Inc. with Similar Stocks
Dashboard
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -49.26
2
Flat results in Dec 25
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
HKD 1,105 Million ()
NA (Loss Making)
NA
0.00%
0.15
112.59%
-2.90
Revenue and Profits:
Net Sales:
7 Million
(Quarterly Results - Jun 2021)
Net Profit:
-279 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1109.15%
0%
1109.15%
6 Months
1202.82%
0%
1202.82%
1 Year
444.12%
0%
444.12%
2 Years
5.11%
0%
5.11%
3 Years
-57.47%
0%
-57.47%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
CANbridge Pharmaceuticals Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-16.02%
EBIT Growth (5y)
21.90%
EBIT to Interest (avg)
-47.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.07
Sales to Capital Employed (avg)
8.22
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-4.22
EV to EBIT
-3.53
EV to EBITDA
-3.60
EV to Capital Employed
-3.55
EV to Sales
106.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
54.20
92.30
-41.28%
Operating Profit (PBDIT) excl Other Income
-87.40
-339.50
74.26%
Interest
2.40
9.30
-74.19%
Exceptional Items
108.80
-96.90
212.28%
Consolidate Net Profit
16.10
-479.90
103.35%
Operating Profit Margin (Excl OI)
-1,854.60%
-3,999.80%
214.52%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -41.28% vs -18.82% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 103.35% vs -14.64% in Dec 2024
About CANbridge Pharmaceuticals Inc. 
CANbridge Pharmaceuticals Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






